Cover Image
市場調查報告書

全球胰臟癌診斷及治療藥市場:癌症及各地區市場區隔

Global Pancreatic Cancer Therapeutics & Diagnostics Market - Segmented by Therapeutic, by Diagnostic and Geography - Growth, Trends and Forecasts (2018 - 2023)

出版商 Mordor Intelligence LLP 商品編碼 353881
出版日期 內容資訊 英文 115 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球胰臟癌診斷及治療藥市場:癌症及各地區市場區隔 Global Pancreatic Cancer Therapeutics & Diagnostics Market - Segmented by Therapeutic, by Diagnostic and Geography - Growth, Trends and Forecasts (2018 - 2023)
出版日期: 2018年02月08日 內容資訊: 英文 115 Pages
簡介

本報告提供全球胰臟癌診斷及治療藥市場相關調查,市場趨勢與今後的成長預測,癌症的各類型、各治療法、各診斷、各地區趨勢,及打入市場的主要企業簡介等彙整資料。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義
  • 推動市場的要素
  • 阻礙市場的要素
  • 市場機會
  • 課題

第4章 波特五力分析

第5章 市場區隔

  • 癌症的各類型
    • 外分泌
    • 內分泌
  • 各治療法
    • 手術
    • 放射治療
    • 化療
    • 化學放射線
    • 標靶治療
  • 各診斷
    • ERCP
    • 證實穿刺切片檢查
    • 超音波內視鏡
    • 腹腔鏡
    • 電腦斷層掃描
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 日本
    • 新加坡

第6章 競爭環境

第7章 企業簡介

第8章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 32039

The global pancreatic cancer therapeutics & diagnostics market was valued at USD 2,272.40 million in 2017, and is expected to witness a CAGR 5.6% during 2018 to 2023 (henceforth referred to as the forecast period). Pancreatic cancer accounts for about 3% of all cancers in the United States and about 7% of the cancer deaths and in Europe, pancreatic cancer is the 4th leading cause of death.

Accelerating the therapy for treating the pancreatic cancer

A number therapies has been accelerated in the very less span of time and chemotherapy is the most common form of treatment provided by medical practitioners and other emerging chemotherapies are for the advanced pancreatic cancer combined with agents already approved for use. The one treatment commonly used for the pancreatic cancer is radiation therapy. Radiotherapy uses high energy x-rays (radiation) to destroy the cancer cells. The latest Cancer Research UK states that around 9,400 people are diagnosed with pancreatic cancer each year in the UK and around 8,800 people die from the disease each year and 514 patients are suffering in Europe with pancreatic cancer. Following the surgery, all the patients are been treated with chemo radiotherapy which is increasing the usage of its market.

Drugs and its side effects

As many drugs have been prescribed for the treatment of pancreatic cancer and those drugs have adverse effects, ranging from mild to severe. Very mild fever, loss in appetite, vomiting, and skin rashes can be related with the usage of most of the drugs used to treat pancreatic cancer. There are many list of drugs such as; Tarceva, a drug which is used to treat pancreatic cancer, can lead to pregnancy-related problems, and sometimes, even harm the fetus and can also cause complete failure of liver and kidney functioning. People who have used Afinitor as a treatment regimen for pancreatic cancer have reported losses in appetite, multiple infections, hypercholesterolemia, headache, pneumonitis, stomatitis, diarrhea, asthenia, weight loss etc. The possibility of multiple side effects, with a few that can even cause death results in the reluctance in prescribing drugs to patients. The usage of drugs causes its side effects and acts as a major restraint to the global pancreatic cancer drugs market.

China becomes one of the fastest growing market for Pancreatic Cancer

According to the 2015 oncology annals, pancreatic cancer in China is the 9th/6th leading death cause from cancer for men and woman, respectively. Around 90,000 patients were diagnosed with the pancreatic cancer and 79,400 patients in China with pancreatic cancer died in 2015. Despite many recent improvements of diagnostic techniques, most pancreatic cancer patients were diagnosed at advanced states. Radical resection, alone or in combination with other therapy, is the only way to eliminate pancreatic cancer. Only 10%-20% of patients with pancreatic cancer, who have radical resection, can survive up to 5 years. So, it is necessary to underscore the need for better preoperative staging and more effective systemic therapy. The rising rate of pancreatic cancer and improving access to cancer diagnosis and treatment centers in China are the major driving contributing factors which lead to the exceptional growth of Pancreatic Cancer Therapeutics and Diagnostics Market in China.

Key Developments in the Market

October, 2017: Amgen and CytomX Therapeutics Announce Strategic Collaboration in Immuno-Oncology

September, 2017: FDA Approves Amgen and Allergan's MVASI™ (bevacizumab-awwb) For the Treatment of Five Types of Cancer

May, 2017: NantKwest, NantCell to Test NANT Vaccine in Phase 1/2 Trial for Pancreatic Cancer Patients

Key players of this market are ELI LILLY, AMGEN Inc., F. HOFFMANN-LA ROCHE, CLOVIS ONCOLOGY Inc., PFIZER, NOVARTIS AG and THRESHOLD PHARMACEUTICALS Inc.

Reasons to Purchase this Report

Current and future pancreatic cancer market outlook in the developed and emerging markets

Analyzing various perspectives of the market with the help of Porter's five forces analysis

The segment that is expected to dominate the market

Regions that are expected to witness fastest growth during the forecast period

Identify the latest developments, market shares and strategies employed by the major market players.

3 months analyst support along with the Market Estimate sheet in excel.

Customization of the Report

This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.

Table of Contents

1. INTRODUCTION

  • 1.1 MARKET DEFINITION

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. KEY INFERENCES

5. MARKET OVERVIEW

  • 5.1 CURRENT MARKET SCENARIO
  • 5.2 PORTER'S FIVE FORCES ANALYSIS
    • 5.2.1 BARGAINING POWER OF SUPPLIERS
    • 5.2.2 BARGAINING POWER OF CONSUMERS
    • 5.2.3 THREATS OF NEW ENTRANTS
    • 5.2.4 THREAT OF SUBSTITUTE PRODUCT AND SERVICES
    • 5.2.5 COMPETITIVE RIVALRY WITHIN THE INDUSTRY

6. DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES ANALYSIS (DROC)

  • 6.1 MARKET DRIVERS
    • 6.1.1 INCREASING INCIDENCE AND PREVALENCE OF PANCREATIC CANCER
    • 6.1.2 UNMET THERAPY NEEDS FOR PANCREATIC CANCER
    • 6.1.3 ADVANCEMENTS IN MOLECULAR BIOLOGY AND DEVELOPMENT OF DRUGS
  • 6.2 MARKET RESTRAINTS
    • 6.2.1 DRUG TOXICITY OR DRUG SIDE EFFECTS
    • 6.2.2 HIGH COSTS ASSOCIATED WITH TREATMENTS
  • 6.3 OPPORTUNITIES
  • 6.4 KEY CHALLENGES

7. MARKET SEGMENTATION

  • 7.1 SEGMENTATION-BY THERAPEUTIC
    • 7.1.1 PACLITAXEL ALBUMIN (ABRAXANE)
    • 7.1.2 EVEROLIMUS (AFINITOR)
    • 7.1.3 ERLOTINIB HYDROCHLORIDE (TARCEVA)
    • 7.1.4 FLUOROURACIL
    • 7.1.5 GEMCITABINE HYDROCHLORIDE
    • 7.1.6 IRINOTECAN HYDROCHLORIDE
    • 7.1.7 MITOMYCIN C
    • 7.1.8 SUNITINIB MALATE (SUTENT)
    • 7.1.9 OTHERS
  • 7.2 BY DIAGNOSTIC
    • 7.2.1 IMAGING
    • 7.2.2 BIOPSY
    • 7.2.3 ENDOSCOPY
    • 7.2.4 OTHERS
  • 7.3 SEGMENTATION-BY GEOGRAPHY
    • 7.3.1 NORTH AMERICA
      • 7.3.1.1 UNITED STATES
      • 7.3.1.2 CANADA
      • 7.3.1.3 MEXICO
    • 7.3.2 EUROPE
      • 7.3.2.1 FRANCE
      • 7.3.2.2 GERMANY
      • 7.3.2.3 UNITED KINGDOM
      • 7.3.2.4 ITALY
      • 7.3.2.5 SPAIN
      • 7.3.2.6 REST OF EUROPE
    • 7.3.3 ASIA-PACIFIC
      • 7.3.3.1 CHINA
      • 7.3.3.2 JAPAN
      • 7.3.3.3 INDIA
      • 7.3.3.4 AUSTRALIA & NEW ZEALAND
      • 7.3.3.5 SOUTH KOREA
      • 7.3.3.6 REST OF ASIA-PACIFIC
    • 7.3.4 MIDDLE EAST & AFRICA
      • 7.3.4.1 GCC
      • 7.3.4.2 SOUTH AFRICA
      • 7.3.4.3 REST OF THE MIDDLE EAST & AFRICA
    • 7.3.5 SOUTH AMERICA
      • 7.3.5.1 BRAZIL
      • 7.3.5.2 ARGENTINA
      • 7.3.5.3 REST OF SOUTH AMERICA

8. COMPETITIVE LANDSCAPE

  • 8.1 MERGERS & ACQUISITION ANALYSIS
  • 8.2 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS
  • 8.3 NEW PRODUCTS LAUNCHES

9. KEY PLAYERS

  • 9.1 GENENTECH INC.
  • 9.2 ELI LILLY
  • 9.3 PFIZER
  • 9.4 AMGEN INC.
  • 9.5 CELGENE CORPORATION
  • 9.6 NOVARTIS INTERNATIONAL AG
  • 9.7 IPSEN PHARMACEUTICALS
  • 9.8 BIORAD LABORATORIES INC.
  • 9.9 F. HOFFMANN-LA ROCHE
  • 9.10 CLOVIS ONCOLOGY INC.,
  • 9.11 BECKMAN COULTER

10. FUTURE OF THE MARKET

Back to Top